The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A pyrrolopyrimidine that is 7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine which has been substituted at position 5 by a 4-fluoro-2,3-dihydro-1H-indol-5-yl group, the nitrogen of which has been acylated by a (6-methylpyridin-2-yl)acetyl group. An orally bioavailable PERK inhibitor.
GSK2656157 inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [Palmitic Acid results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [Palmitic Acid results in increased expression of ATF4 protein]; GSK2656157 inhibits the reaction [pegaspargase promotes the reaction [ATF4 protein binds to FGF21 promoter]]; GSK2656157 inhibits the reaction [perfluorooctanoic acid results in increased expression of ATF4 protein]; GSK2656157 inhibits the reaction [Thapsigargin results in increased expression of ATF4 protein] GSK2656157 inhibits the reaction [[INS co-treated with Acrylamide] results in increased expression of ATF4 protein]
GSK2656157 inhibits the reaction [Palmitic Acid results in increased expression of DDIT3 mRNA]; GSK2656157 inhibits the reaction [Palmitic Acid results in increased expression of DDIT3 protein] GSK2656157 inhibits the reaction [6-methoxyflavone results in increased expression of DDIT3 protein] GSK2656157 inhibits the reaction [[INS co-treated with Acrylamide] results in increased expression of DDIT3 protein]
GSK2656157 promotes the reaction [shikonin inhibits the reaction [Glutamic Acid results in increased phosphorylation of EIF2AK3 protein]] GSK2656157 inhibits the reaction [6-methoxyflavone results in increased phosphorylation of EIF2AK3 protein] GSK2656157 results in decreased activity of EIF2AK3 protein
GSK2656157 inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; GSK2656157 inhibits the reaction [Palmitic Acid results in increased phosphorylation of EIF2S1 protein] GSK2656157 promotes the reaction [shikonin inhibits the reaction [Glutamic Acid results in increased phosphorylation of EIF2S1 protein]] GSK2656157 inhibits the reaction [6-methoxyflavone results in increased phosphorylation of EIF2S1 protein]; GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]
GSK2656157 inhibits the reaction [pegaspargase results in decreased expression of FGF21 mRNA] GSK2656157 inhibits the reaction [pegaspargase promotes the reaction [ATF3 protein binds to FGF21 promoter]]; GSK2656157 inhibits the reaction [pegaspargase promotes the reaction [ATF4 protein binds to FGF21 promoter]]; GSK2656157 inhibits the reaction [pegaspargase results in decreased expression of FGF21 protein]
GSK2656157 inhibits the reaction [[INS co-treated with Acrylamide] results in increased expression of ATF4 protein]; GSK2656157 inhibits the reaction [[INS co-treated with Acrylamide] results in increased expression of BAX protein]; GSK2656157 inhibits the reaction [[INS co-treated with Acrylamide] results in increased expression of DDIT3 protein]; GSK2656157 inhibits the reaction [[INS co-treated with Acrylamide] results in increased phosphorylation of EIF2A protein]
browse the term
